EA201500080A1 - Способ in vitro диагностирования и мониторинга рака - Google Patents
Способ in vitro диагностирования и мониторинга ракаInfo
- Publication number
- EA201500080A1 EA201500080A1 EA201500080A EA201500080A EA201500080A1 EA 201500080 A1 EA201500080 A1 EA 201500080A1 EA 201500080 A EA201500080 A EA 201500080A EA 201500080 A EA201500080 A EA 201500080A EA 201500080 A1 EA201500080 A1 EA 201500080A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- cancer
- monitoring
- cells
- vitro diagnosis
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4915—Blood using flow cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
- G01N2333/7155—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ecology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
В заявке описан способ in vitro диагностирования, и/или мониторинга, и/или прогнозирования развития ракового заболевания, отличающийся тем, что определяют по меньшей мере в одном образце соотношение между Treg-клетками и по меньшей мере одной другой группой Т-клеток, представляющей собой группу Th17-клеток, Th1-клеток и/или Th2-клеток.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20120174539 EP2682750A1 (en) | 2012-07-02 | 2012-07-02 | In vitro method for the diagnosis and surveillance of cancer |
US201261672941P | 2012-07-18 | 2012-07-18 | |
PCT/EP2013/063448 WO2014005909A1 (en) | 2012-07-02 | 2013-06-27 | In vitro method for the diagnosis and surveillance of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201500080A1 true EA201500080A1 (ru) | 2015-06-30 |
Family
ID=46397089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201500080A EA201500080A1 (ru) | 2012-07-02 | 2013-06-27 | Способ in vitro диагностирования и мониторинга рака |
Country Status (18)
Country | Link |
---|---|
US (1) | US20150337384A1 (ru) |
EP (2) | EP2682750A1 (ru) |
JP (1) | JP2015526709A (ru) |
KR (1) | KR20150035521A (ru) |
CN (1) | CN104364656A (ru) |
AU (1) | AU2013286134A1 (ru) |
BR (1) | BR112014026661A2 (ru) |
CA (1) | CA2872668A1 (ru) |
CL (1) | CL2014002975A1 (ru) |
EA (1) | EA201500080A1 (ru) |
HK (1) | HK1202618A1 (ru) |
IL (1) | IL236197A0 (ru) |
IN (1) | IN2015DN00678A (ru) |
MX (1) | MX2014013079A (ru) |
PH (1) | PH12014502436A1 (ru) |
SG (1) | SG11201406581UA (ru) |
WO (1) | WO2014005909A1 (ru) |
ZA (1) | ZA201409298B (ru) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
EP3111221B2 (en) | 2014-02-24 | 2022-01-19 | Ventana Medical Systems, Inc. | Methods, kits, and systems for scoring the immune response to cancer by simultaneous detection of cd3, cd8, cd20 and foxp3. |
EP3129034A4 (en) * | 2014-03-14 | 2017-11-22 | Brian J. Czerniecki | Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration |
US20160266125A1 (en) * | 2015-03-12 | 2016-09-15 | John Wayne Cancer Institute | Methods of treating and predicting progression of cancer based on t cell subsets |
US20180193391A1 (en) * | 2015-06-22 | 2018-07-12 | President And Fellows Of Harvard College | Induction of lamina propria regulatory t cells |
JP6100867B1 (ja) * | 2015-11-06 | 2017-03-22 | 振武 曽 | 免疫状態の分析のための検査方法 |
CN106932576A (zh) * | 2017-03-22 | 2017-07-07 | 山东大学深圳研究院 | 一种人调节性t细胞的免疫抑制功能的检测方法 |
US11573234B2 (en) | 2017-05-19 | 2023-02-07 | Royal Melbourne Institute Of Technology | Predicting responders to cyclophosphamide therapy |
TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
CN108508196B (zh) * | 2018-04-13 | 2020-10-27 | 何韶衡 | 一种检测人调节性t细胞亚型的试剂盒及检测方法 |
AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
JP7259019B2 (ja) * | 2018-09-20 | 2023-04-17 | ヴェンタナ メディカル システムズ, インク. | フローサイトメトリデータを分析するためのサイズに基づくゲーティング |
-
2012
- 2012-07-02 EP EP20120174539 patent/EP2682750A1/en not_active Withdrawn
-
2013
- 2013-06-27 CN CN201380030845.9A patent/CN104364656A/zh active Pending
- 2013-06-27 KR KR20147030813A patent/KR20150035521A/ko not_active Application Discontinuation
- 2013-06-27 WO PCT/EP2013/063448 patent/WO2014005909A1/en active Application Filing
- 2013-06-27 CA CA2872668A patent/CA2872668A1/en not_active Abandoned
- 2013-06-27 SG SG11201406581UA patent/SG11201406581UA/en unknown
- 2013-06-27 EP EP13731798.8A patent/EP2867677A1/en not_active Withdrawn
- 2013-06-27 US US14/410,365 patent/US20150337384A1/en not_active Abandoned
- 2013-06-27 MX MX2014013079A patent/MX2014013079A/es unknown
- 2013-06-27 BR BR112014026661A patent/BR112014026661A2/pt not_active IP Right Cessation
- 2013-06-27 IN IN678DEN2015 patent/IN2015DN00678A/en unknown
- 2013-06-27 JP JP2015519081A patent/JP2015526709A/ja active Pending
- 2013-06-27 EA EA201500080A patent/EA201500080A1/ru unknown
- 2013-06-27 AU AU2013286134A patent/AU2013286134A1/en not_active Abandoned
-
2014
- 2014-10-30 PH PH12014502436A patent/PH12014502436A1/en unknown
- 2014-11-03 CL CL2014002975A patent/CL2014002975A1/es unknown
- 2014-12-11 IL IL236197A patent/IL236197A0/en unknown
- 2014-12-17 ZA ZA2014/09298A patent/ZA201409298B/en unknown
-
2015
- 2015-03-20 HK HK15102870.4A patent/HK1202618A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
HK1202618A1 (en) | 2015-10-02 |
IN2015DN00678A (ru) | 2015-06-26 |
EP2867677A1 (en) | 2015-05-06 |
CN104364656A (zh) | 2015-02-18 |
BR112014026661A2 (pt) | 2017-06-27 |
KR20150035521A (ko) | 2015-04-06 |
AU2013286134A1 (en) | 2015-01-22 |
IL236197A0 (en) | 2015-01-29 |
US20150337384A1 (en) | 2015-11-26 |
WO2014005909A1 (en) | 2014-01-09 |
CL2014002975A1 (es) | 2015-04-24 |
MX2014013079A (es) | 2014-12-08 |
EP2682750A1 (en) | 2014-01-08 |
SG11201406581UA (en) | 2015-01-29 |
JP2015526709A (ja) | 2015-09-10 |
ZA201409298B (en) | 2015-12-23 |
CA2872668A1 (en) | 2014-01-09 |
PH12014502436A1 (en) | 2015-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201500080A1 (ru) | Способ in vitro диагностирования и мониторинга рака | |
EA201590027A1 (ru) | Способы детекции заболеваний или состояний | |
MX367046B (es) | Marcadores especificos de via para diagnosticar sindrome del intestino irritable. | |
WO2014201516A3 (en) | Biomarker identification | |
EP2566983A4 (en) | SERIAL ANALYSIS OF BIOMARKERS FOR THE DIAGNOSIS OF A DISEASE | |
EA201390149A1 (ru) | Способы выявления заболевания или патологических состояний с использованием фагоцитарных клеток | |
BR112015001592A8 (pt) | análise de imagem e medidas de amostras biológicas | |
WO2014028884A3 (en) | Cancer diagnostics using biomarkers | |
MX361731B (es) | Método para diagnosticar cáncer y kit de diagnóstico usando medición de actividad de células nk. | |
MX2015012303A (es) | Un metodo no invasivo para medir el estres oxidativoy daño oxidativo de los biomarcadores cutaneos. | |
NZ629555A (en) | Monocyte biomarkers for cancer detection | |
MX358474B (es) | Biomarcadores salivales específicos para detección de riesgo, diagnóstico temprano, pronóstico y vigilancia de las enfermedades de alzheimer y de parkinson. | |
WO2015095862A3 (en) | Microrna biomarkers for ovarian cancer | |
MX2016001719A (es) | Metodos y equipos para predecir el riesgo de tener una enfermedad o evento cardiovascular. | |
BR112017006315A2 (pt) | agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits | |
MX363679B (es) | Metodo para diagnosticar cancer. | |
GB201200178D0 (en) | Diagnostic method and system | |
TR201906242T4 (tr) | Elektroki̇myasal deteksi̇yon metodu | |
GB201114909D0 (en) | Biomarkers for lysosomal storage disorders | |
NZ720608A (en) | Β-glucan assay methods | |
BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
BR112017002575A2 (pt) | método para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo, kit e sistema para diagnosticar ou monitorar especificamente lupus sistêmico eritematoso em um indivíduo | |
WO2014146035A3 (en) | Compositions and methods for cancer diagnosis | |
WO2019035623A3 (ko) | 렉틴이 결합된 나노입자를 이용한 암 진단 방법 | |
EP4328324A3 (en) | Methods of diagnosing epilepsy |